

33. The anticode oligomer of Claim 32 wherein said anticode oligomer is a phosphorothioate derivative.

34. The anticode oligomer of Claim 32, wherein said anticode oligomer is from about 10 to about 100 nucleotides long.

35. The anticode oligomer of Claim 34, wherein said anticode oligomer is from about 15 to about 24 nucleotides in length.

36. The anticode oligomer of Claim 32, which is complementary to and which binds to a translation-initiation, splicing, transport or degradation site in mRNA or pre-mRNA expressed from the human bcl-2 gene.

37. The anticode oligomer of Claim 32, selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 14 and SEQ ID NO: 17.

38. The anticode oligomer of Claim 37, selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5.

39. A composition for inhibiting growth of tumor cells expressing the human bcl-2 gene, comprising:

- (e) the anticode oligomer of Claim 32, and
- (f) a pharmaceutically acceptable carrier.

40. The composition of Claim 39 wherein said anticode oligomer is a phosphorothioate derivative.

41. The composition of Claim 39, wherein said anticode oligomer is from about 10 to about 100 nucleotides in length.

42. The composition of Claim 41, wherein said anticode oligomer is from about 15 to about 24 nucleotides in length.

43. The composition of Claim 39, wherein said anticode oligomer is complementary to and binds to a translation, splicing, transport or degradation site in mRNA or pre-mRNA or pre-mRNA expressed from the human bcl-2 gene.

44. The composition of Claim 39, wherein said anticode oligomer is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 14 and SEQ ID NO: 17.

45. A vector for transfecting human tumor cells wherein said vector expresses the anticode oligomer of Claim 32.

46. The vector of Claim 45, wherein said anticode oligomer is from about 10 to about 100 nucleotides in length.

47. The vector of Claim 46, wherein said anticode oligomer is from about 15 to 24 nucleotides in length.

48. The vector of Claim 45, wherein said anticode oligomer sequence is complementary to and binds to a translation-initiation, splicing, transport or degradation site in mRNA or pre-mRNA expressed from the human bcl-2 gene.

49. The vector of Claim 45, wherein said anticode oligomer sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 14 and SEQ ID NO: 17.

50. The vector of Claim 49, selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5.

51. A kit comprising the composition of Claim 39 and a chemotherapeutic agent.

52. A kit comprising the vector of Claim 45 and a chemotherapeutic agent.--

REMARKS